Loading stock data…
$0.57-0.03 (-5.75%)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology.
BeyondSpring Inc. in the Healthcare sector is trading at $0.57 with a market capitalization of $31M. The stock is currently near its 52-week low of $0.57, remaining 57.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.73M↑ | -$2.23M↑ | -$2.60M↓ | -$1.79M↑ | -$1.95M |
| Net Income | -$849,000↑ | -$2.16M↓ | -$2.14M↓ | -$1.54M↑ | -$1.81M |
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the...